Form: 8-K

Current report filing

November 1, 2021

8-K: Current report filing

Published on November 1, 2021

0000882291 false 0000882291 2021-10-27 2021-10-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



Washington, D.C. 20549





Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): October 27, 2021


Aethlon Medical, Inc.

(Exact name of registrant as specified in its charter)


Nevada   001-37487   13-3632859
(State or other jurisdiction   (Commission File Number)   (IRS Employer Identification No.)
of incorporation)        

11555 Sorrento Valley Road, Suite 203

San Diego, California

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: 858-459-7800



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol Name of each exchange on which registered
Common Stock AEMD The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 1.01 Entry into a Definitive Material Agreement.


On October 27, 2021, Aethlon Medical, Inc. (the “Company”) entered into a Lease (the “Lease”) with San Diego Inspire 5, LLC, a Delaware limited liability company (the “Landlord”), for the lease of approximately 24,915 square feet of space, consisting of (i) approximately 22,260 square feet of space located at 11588 Sorrento Valley Road, San Diego, California 92121 (the “Building”) and (ii) 2,655 square feet of space located in the Building and commonly known as Suite 18 (the “Suite Premises” and together with the Building, the “Premises”). The Lease is expected to commence on the date upon which the Premises are ready for occupancy or on such date as the Company commences to conduct business on the Premises, and has an initial term of 58 months after the commencement date of the Lease (the “Initial Term”). The Lease provides the Company with an option to extend the Initial Term for one additional renewal term of five years (the “Option Term”). During the first year of the Initial Term, the Company is required to pay base rent of $12,080.25 per month for the Premises. Thereafter, the base rent will increase each year for the Premises and in the fifth year of the Initial Term, the Company is required to pay base rent of $13,593.60 per month for the Premises. If the Company elects to extend the Lease beyond the Initial Term, then the base rent for the Option Term will be the fair rental value (as calculated in the Lease) for the Premises as of the commencement date of the Option Term. The Company will also be responsible for the payment of the Company’s share of certain operating expenses and tax expenses of the buildings, subject to certain exceptions. In the event of a default of certain of the Company’s obligations under the Lease, the Landlord may terminate the Lease and recover damages as provided by the Lease and by law.


The foregoing description of the Lease is only a summary and is qualified in its entirety by the terms of the Lease, a copy of which the Company expects to file as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021.















Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


        Aethlon Medical, Inc.
Dated: November 1, 2021       By:   /s/ James B. Frakes

James B. Frakes

Chief Financial Officer